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Abstract Huisgen’s azide-alkyne cycloaddition reaction was employed to synthesize a series of 1H-1,2,3-
triazole-tethered uracil-ferrocenyl chalcone conjugates with the aim of evaluating their in vitro anti-proliferative 
efficacy on human leukemia (CCRF-CEM) and human breast adenocarcinoma (MDA-MB-468) cell lines. 
Cytotoxic evaluation studies identified a number of synthesized conjugates that inhibited the proliferation of 
leukemia cancer cells by ~70% after 72 h. The selected synthesized conjugates were found to be significantly 
less cytotoxic against normal kidney cell line (LLC-PK1) when compared with CCRF-CEM cancer cells. 
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Introduction 
Cancer, an uncontrolled growth and rapid proliferation of abnormal cells, is one of the most formidable 
challenges in the world (Fadeyi et al., 2008).  Most cancers are recognized by the uninhibited growth of cells 
without demarcation due to the deregulation of crucial enzymes and proteins controlling cell division and 
proliferation (Mareel and Leroy, 2003; Wesche, Haglund and Haugsten, 2011). According to the World 
Health Organization (WHO) report, 8.2 million people died of cancer all over the world in 2016 
(https://www.cancer.org/research/cancer-facts-statistics.html). A recent survey by American Cancer Society of 
epidemiologists revealed that out of 595,690 cancer deaths in the US, 188,800 was because of cigarette 
smoking. In addition, 20% of all cancers are associated with body fatness, physical inactivity, excess alcohol 
consumption, and/or poor nutrition while certain cancers are related to infections caused by human 
papillomavirus (HPV), hepatitis B virus (HBV), hepatitis C virus (HCV), human immunodeficiency virus 
(HIV), and Helicobacter pylori.
 
Although much progress has aspired from the diagnosis to the treatment of 
cancer, the factors like poor patient compliance, drug resistance, and drug-induced toxicities have provided a 
strong impetus for the discovery and development of novel cancer chemotherapeutic agents of clinical 
significance (Grant 2009; Solyanik 2011; Vijayaraghavalu et al., 2012). 
The recognition of ferrocene and its derivatives for biological explorations may be ascribed to their 
stability in aqueous and aerobic media, aptness of derivatization, and appropriate electrochemical 
properties (Allardyce et al., 2005; Fouda et al., 2007; Ornelas et al., 2011). The anticancer activities of 
ferrocene derivatives were first reported by Fiorina and co-workers against lymphocytic leukemia P-388 
(Fiorina, Dubois and Brynes, 1978). Ferrocene derivative of the anti-estrogen tamoxifen has also 
displayed interesting antiproliferative properties, which have been attributed to its redox behavior 
(Hillard et al., 2006; Hillard et al., 2006; Duivenvoorden et al., 2005). 
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The anticancer activities of 2-ferrocenyl-1,1-diphenylbut-1-ene against HL-60, HCT-8, SF-295, MDA-
MB-435, OVCAR-8 and GBM non-cancerous cells were reported by de Oliveira and co-workers, 
(Oliveira et al., 2014) suggesting the potential of conjugating ferrocene with other anticancer agents. A 
series of ferrocenyl-catechol conjugates were synthesized by Tan and co-workers and evaluated for their 
cytotoxicity against MDA-MB-231 cancer cell lines. The conjugates exhibited better anticancer 
activities (IC50 = 0.48-1.21 μM) compared to their corresponding phenolic analogs (0.57-12.70 μM) 
(Tan et al., 2012). One of the privileged structures in drug discovery is uracil that has diverse 
pharmacological profiles, synthetic accessibility, and the ability to bestow drug-like properties to the 
compound libraries appended to them (Newkome 1982). 5-Fluorouracil (5-FU), an anti-metabolism 
drug, is widely used in the treatment of malignancies, such as colorectal, stomach and breast cancer. 
However, its poor selectivity along with high incidences of bone marrow, gastrointestinal tract, and 
central nervous toxicity has limited its therapeutic importance (Pan et al., 2011). To address these 
problems, modifications of 5-FU have been accomplished resulting in the development of 5-FU 
derivatives viz. floxuridine and tegafur exhibiting improved pharmacological and pharmacokinetic 
properties (Ohwada et al., 2009). 5-FU-Camptothecin (CPT) conjugate, a topoisomerase cytotoxic 
alkaloid has exhibited comparable cytotoxicity to irinotecan (semi-synthetic analog of CPT) with 
enhanced selectivity, efficacy and safety (Li et al., 2012). 
 The prevalence of chalcones as a major constituent or a substituent in varied biologically active 
compounds represent another important structural motif, synthetically manoeuvered for the 
development of efficacious drugs against tropical diseases and cancer (Singh, Anand and Kumar, 2014). 
Chalcones have congregated considerable attention for their cytotoxic activities because of their similar 
mode of action to the structurally related combretastatin (Pettit et al., 2005). Chalcone is considered a 
promising template for the development of HIF-1 inhibitors, a major mechanism for the survival and 
evasion of tumor cells (Srinivasan, Johnson and Xing, 2011).  
The recent revelation from our laboratory has shown the synthesis and cytotoxic potential of 1H-1,2,3-
triazole-tethered β-lactam-chalcone conjugates with activity mainly dependent upon the nature of 
substituents present at aryl rings of chalcone as well as at N-1 position of the β-lactam ring (Singh et al., 
2012). In continuation of our efforts for the synthesis of biologically relevant heterocycles using 
molecular hybridization, (Singh et al., 2017; Raj et al., 2015; Kumar et al., 2012; Kumar et al., 2013., 
Singh et al. 2014) the present work describes the synthesis of uracil-ferrocenyl chalcone conjugates, 
along with an evaluation of their in vitro antiproliferative efficacy on human leukemia (CCRF-CEM,) 
and human breast adenocarcinoma (MDA-MB-468) cell lines. 
 
Experimental Section 
 
Melting points were determined by an open capillary using a Veego Precision Digital Melting Point apparatus 
(MP-D) and are uncorrected. 
1
H NMR spectra were recorded in DMSO with a BRUKER AVANCE II (500 
MHz) spectrometer using TMS as an internal standard. Chemical shift values are expressed as parts per million 
downfield from TMS and J values are in hertz. Splitting patterns are indicated as s: singlet, d: doublet, t: triplet, 
m: multiplet, dd: double doublet, ddd: doublet of a doublet of a doublet, and br: broad peak. 
13
C NMR spectra 
were recorded in DMSO with a BRUKER AVANCE II (125 MHz) using TMS as internal standard. Mass 
spectra were recorded on a BRUCKER high-resolution mass spectrometer (micrOTOF-QII). Elemental analyses 
were performedon a Heraus CHN-O-Rapid Elemental Analyzer. Column chromatography was performed on 
silica gel (60–120 mesh) using ethyl chloroform:hexane mixture as eluent. 
General procedure for the synthesis of uracil-ferrocenyl chalcone conjugates (5a-r): To a stirred 
solution of O-propargylated ferrocenylchalcone 4 (1 mmol) and N-alkylated-azido-uracil 3 (1 mmol) in 
an ethanol:water mixture was added copper sulfate (0.05 mmol) and sodium ascorbate (0.13 mmol). The 
reaction mixture was allowed to stir at room temperature for 10−12 h, and the progress was monitored 
using TLC. After the completion of reaction, water (20 mL) was added, and the reaction mixture was 
extracted twice with dichloromethane (2 × 30 mL). The combined organic layers were dried over 
anhydrous sodium sulfate and concentrated under reduced pressure to yield a crude product, which was 
purified via column chromatography using a 5:95 (methanol:chloroform, v/v) mixture. 
 
1-(2-{4-[4-(3-ferrocenyl-acryloyl)-phenoxymethyl]-[1,2,3]triazol-1-yl}-ethyl)-1H-pyrimidine-2,4-dione 
(5a): Yield 85%; Dark red solid, m.p: 210-211
o
C; 
1
H NMR (DMSO-d6, 500 MHZ): 4.10 (s, 5H, H
1
), 
4.16 (s, 2H, H
9
), 4.42 (s, 2H, H
3
), 4.58 (s, 2H, H
2
), 4.65 (s, 2H, H
8
), 5.20 (s, 2H, H
6
), 5.30 (d, J=7.5Hz, 
1H, H
11 
), 6.79 (d, J=7.5Hz, 1H, H
10
), 7.01-7.12 (m, 2H, Ar-H), 7.14 (d, J=15.1Hz, 1H, H
4
), 7.61 (s, 1H, 
H
7 
), 7.71 (d, J=15.1Hz, 1H, H
5
), 7.99-8.02 (m, 2H, Ar-H), 7.92 (s, 1H, H
7
), 11.19 (NH-exchangeable 
with D2O); 
13
C NMR (DMSO, d
6
, 125 MHz): 48.2,  48.5, 61.7,  69.0,  69.7, 71.4, 84.8, 102.1, 114.6, 
114.7, 118.8, 125.0, 130.5, 143.2, 144.6, 145.7, 150.3, 159.8, 163.9, 187.7. HRMS calcd for 
C28H25FeN5O4 [M]
+ 
551.1256, Found: 551.1270 Anal Calcd(%) for: C, 60.99; H, 4.57; N, 12.70:  C, 
60.82; H, 4.62; N, 12.66. 
1-(3-{4-[4-(3-ferrocenyl-acryloyl)-phenoxymethyl]-[1,2,3]triazol-1-yl}-propyl)-1H-pyrimidine-2,4-
dione (5b): Yield  83%. Dark red solid, m.p: 195-196 
o
C; 
1
H NMR (DMSO-d6, 500 MHz):  2.10-2.19 
(m, 2H, H
11
), 3.73 (t,  J=6.7Hz, 2H, H
10
), 4.19  (s, 5H, H
1
), 4.43 (t, J=6.7Hz, 2H, H
8
), 4.53 (s, 2H, H
2
), 
4.85 (s, 2H, H
3
), 5.27 (s, 2H, H
6
), 5.55 (d, J=7.0Hz, 1H, H
12
), 7.19 (d, J=7.5, 2H, Ar-H), 7.45 (d, 
J=15.3Hz, 1H, H
5
), 7.61-7.65 (m, 2H, H
4
+H
11
), 8.08 (d, J=7.3Hz, 2H, Ar-H), 8.29  (s, 1H, H
7
), 11.23 
(NH-exchangeable with D2O); 
13
C NMR (DMSO-d
6
, 125 MHz): 29.5,  45.5,  47.4,  61.8, 69.6, 69.9, 
71.5, 79.7, 101.6, 115.1, 119.3, 125.2, 131.0, 131.4, 142.7, 145.7, 145.9,  151.4,  162.1, 164.2, 187.0 
C29H27FeN5O4 [M]
+
 565.1412 Found: 565.1489 Anal Calcd(%) for: C, 61.60; H, 4.81; N, 12.39.Found: 
C, 61.82; H, 4.72; N, 12.50. 
1-(4-{4-[4-(3-ferrocenyl-acryloyl)-phenoxymethyl]-[1,2,3]triazol-1-yl}-butyl)-1H-pyrimidine-2,4-dione 
(5c): Yield 79%. Dark red solid, m.p: 187-188 
o
C; 
1
H NMR (DMSO-d6,500 MHz): 1.57(t, J=6.7Hz, 2H, 
H
10
), 1.80 (t, J=7.2Hz, 2H, H
9
), 3.75 (t, J=6.4Hz, 2H, H
11
), 4.13(s, 5H, H
1
), 3.38 (t, J=6.1Hz, 2H, 
H
8
),4.51 (s, 2H, H
2
), 4.82 (s, 2H, H
3
), 5.20 (s, 2H, H
6
),5.57 (d, J=7.3Hz, 1H, H
13
), 7.13 (d, J=8.1Hz, 2H, 
ArH), 7.40 (d, J=15.1Hz,1H, H
5
), 7.60 (d, J=15.1Hz, 1H, H
4
), 7.65 (d, J=7.3Hz, 1H, H
12
), 8.01 (d, 
J=8.5Hz, 2H, Ar-H), 8.20 (s,1H,H
7
), 11.73 (NH-exchangeable with D2O); 
13
C NMR (DMSO-d6, 125 
MHz): 25.7, 27.2, 47.6, 49.5, 61.5, 69.5, 69.8, 71.3, 79.6, 101.3, 115.4, 119.4, 125.0, 131.1,131.2, 
142.8, 145.7, 150.5, 160.5, 162.4, 187.1. C30H29FeN5O4 [M]
+
579.1569. Found: 579.1578. Anal Calcd 
(%) for: C, 62.19; H, 5.04; N, 12.09.Found: C, 62.29; H, 5.14; N, 12.15. 
1-(5-{4-[4-(3-ferrocenyl-acryloyl)-phenoxymethyl]-[1,2,3]triazol-1-yl}-pentyl)-1H-pyrimidine-2,4-
dione (5d): Yield 84%. Dark red solid, m.p: 179-180
o
C; 
1
H NMR (DMSO-d6, 500 MHz): 1.20-1.22  
(m,2H,H
10
), 1.67 (t, J=6.7Hz, 2H, H
11
), 1.83 (t, J=7.5Hz, 2H, H
9
), 3.63 (t, J=7.0Hz, 2H, H
12
), 4.13 (s, 
5H, H
1
), 4.37 (t,J=7.3Hz, 2H, H
8
), 4.52 (s, 2H, H
2
), 4.83 (s, 2H, H
3
), 5.21 (s, 2H, H
6
), 5.54 (d, J=7.8Hz, 
1H, H
14
), 7.13 (d,J=8.2Hz, 2H, Ar-H), 7.41 (d,  J=15.5Hz, 1H, H
5
), 7.65 (d, J=7.8Hz, 1H, H
13
), 7.66 (d, 
J=15.5Hz, 1H, H
4
), 8.08 (d, J=8.2Hz, 2H, Ar-H), 8.27 (s, 1H, H
7
), 11.73 (NH-exchangeable with D2O); 
13
C NMR (DMSO-d6, 125 MHz); 23.3, 28.4, 29.3, 48.3, 49.4, 61.6, 69.7, 69.8, 71.4, 79.5, 101.1, 115.2, 
119.2,  125.1, 131.2, 131.3, 142.7, 145.4, 150.4, 160.3, 162.3, 187.2.C31H31FeN5O4 [M]
+ 
593.1725. 
Found: 593.1747. Anal Calcd (%) for: C, 62.74; H, 5.27; N, 11.80.Found: C, 62.81; H, 5.15; N, 11.72. 
1-(6-{4-[4-(3-ferrocenyl-acryloyl)-phenoxymethyl]-[1,2,3]triazol-1-yl}-hexyl)-1H-pyrimidine-2,4-dione 
(5e): Yield 79%. Dark red solid,  m.p: 170-171
o
C; 
1
H NMR (DMSO-d6, 500 MHz): 1.26-1.27 (m, 4H, 
H
10
+H
11
), 1.52-1.54 (m, 2H, H
12
), 1.81-1.83 (m, 2H, H
9
), 3.47 (t, J=7.3Hz, 2H, H
13
), 4.04 (s, 5H, H
1
), 
4.25 (t,J=1.5Hz, 2H, H
2
), 4.34 (t, J=7.2Hz, 2H, H
5
), 4.71 (t, J=1.7Hz, 2H, H
3
), 5.24 (s, 2H, H
6
), 5.35 (d, 
J=7.1Hz, 1H, H
15
), 7.15 (d, J=7.3Hz, 2H, Ar
_
H), 7.43 (d, J=15.2Hz,1H, H
5
), 7.62
_
7.63 (m, 2H, 
H
4
+H
14
), 8.06 (d, J=7.3Hz, 2H, Ar-H), 8.27 (s, 1H, H
7
), 11.22  (NH-exchangeable with D2O); 
13
C NMR 
(DMSO-d6, 125 MHz): 25.1, 25.2, 28.5, 29.6, 48.2, 49.3, 61.6, 69.5, 69.6, 71.3, 79.3, 101.2, 115.3, 
119.3, 125.2, 131.2, 131.3, 142.7, 145.7, 146.1, 150.3, 160.2, 162.6, 187.4. HRMS calcd for 
C32H33FeN5O4 [M]
+ 
607.1882. Found: 607.1876. Anal Calcd (%) for: C,63.27; H, 5.48; N, 11.53.Found 
C,63.33; H,5.38; N,11.43 
1-(8-{4-[4-(3-ferrocenyl-acryloyl)-phenoxymethyl]-[1,2,3]triazol-1-yl}-octyl)-1H-pyrimidine-2,4-dione 
(5f): Yield 80%. Dark red solid, m.p: 151-152
o
C; 
1
H NMR (DMSO-d6, 500MHz): 1.21-1.25 (m, 8H, 
H
10
+H
11
+H
12
+H
13
), 1.52 (t, J=6.7Hz, 2H, H
14
), 1.79 (t, J=6.8Hz, 2H, H
9
), 3.60 (t, J=7.1Hz, 2H, H
15
), 
4.17 (s, 5H, H
1
), 4.34 (t, J=6.8Hz, 2H, H
9
), 4.51(s, 2H, H
2
), 4.83 (s, 2H, H
3
), 5.25 (s, 2H, H
6
), 5.51 (d, 
J=7.7Hz, 1H, H
17
), 7.16 (d, J=8.6Hz, 2H, Ar-H), 7.43 (d, J=15.2Hz, 1H, H
4
), 7.59-7.62( m, 2H, 
H
5
+H
16
), 8.06 (d, J=8.5Hz, 2H, Ar-H) ,8.24 (s, 1H, H
7
), 11.17 (NH-exchangeable with D2O); 
13
C NMR 
(DMSO-d6, 125 MHz): 26.1,  26.2,  28.6,  28.8,  28.9, 30.0, 47.8, 49.8, 61.8, 69.6, 69.9, 71.5, 79.7, 
101.2, 115.1, 119.3, 125.0, 131.0, 131.4, 142.6, 145.7, 146.1, 151.3, 162.0, 164.1, 187.0. HRMS calcd 
for C34H37FeN5O4 [M]
+ 
635.2195. Found: 635.2184. Anal Calcd(%) for: C, 64.26;  H, 5.58;  N, 
11.02.Found: C, 64.31;  H, 5.74;  N, 11.10. 
5-Chloro-1-(2-{4-[4-(3-ferrocenyl-acryloyl)-phenoxymethyl]-[1,2,3]triazol-1-yl}-ethyl)-1H-pyrimidine-
2,4-dione (5g): Yield 83%; Dark red solid, m.p: 186-187
o
C: 
1
H NMR (DMSO-d6, 500MHZ): 4.14 (s, 
2H, H
9
), 4.18 (s, 5H, H
1
), 4.53 (s,2H, H
2
), 4.68 (s, 2H, H
3
), 4.84 (s, 2H, H
8
), 5.25 (s, 2H, H
6
), 7.15-7.17  
(m, 2H, Ar-H), 7.44  (d,  J=15.0Hz, 1H, H
5
),  7.62 (d, J=15.0Hz, 1H, H
4
), 7.78 (s, 1H, H
7
), 8.06-8.08 
(m, 2H, Ar-H),  8.27 (s, 1H, H
10
), 11.85 (NH-exchangeable with D2O); 
13
C NMR (DMSO
_
d
6
, 125 
MHz): 48.1, 48.3, 61.7, 61.9, 69.6, 71.6, 79.7, 106.8, 115.1, 119.2, 125.7, 131.0, 131.4, 142.9, 145.6, 
145.8, 150.4, 159.8, 162.0, 187.0. HRMS calcd for C28H24ClFeN5O4 [M]
+ 
585.0866. Found: 585.0876 
Anal Calcd(%) for: C, 57.41; H, 4.13; N, 11.95; Found: C, 57.35; H, 4.19; N, 11.84.  
5-Chloro-1-(3-{4-[4-(3-ferrocenyl-acryloyl)-phenoxymethyl]-[1,2,3]triazol-1-yl}-propyl)-1H-
pyrimidine-2,4-dione (5h): Yield 80%. Dark red solid, m.p: 170-171 
o
C; 
1
H NMR (DMSO-d6, 500 
MHz): 2.13-2.21 (m, 2H, H
11
), 3.75 (t, J=6.3Hz, 2H, H
10
), 4.20 (s, 5H, H
1
), 4.45 (t, J=6.4Hz, 2H, H
8
), 
4.55 (s, 2H, H
2
), 4.86 (s, 2H, H
3
) ,5.29 (s, 2H, H
6
), 7.17 (d, J=7.2Hz, 2H, Ar-H),7.42 (d, J=15.1Hz, 1H, 
H
5
), 7.62-7.66 (m, 2H, H
5
+H
11
),  8.06 (d, J=7.3Hz, 2H, Ar-H), 8.27(s, 1H, H
7
), 11.25 (NH-
exchangeable with D2O; 
13
C NMR (DMSO-d6, 125 MHz): 29.3,  45.3, 47.5,  61.7, 69.5, 69.6, 71.4, 
79.5, 105.4, 115.3, 119.4, 125.4, 131.2, 131.5, 142.5, 145.5, 145.8, 151.6, 162.3, 164.5, 187.2. 
C29H26ClFeN5O4 [M]
+
 599.1023 Found: 599.1072 Anal Calcd (%) for: C, 58.07; H, 4.37; N, 11.68. 
Found: C, 58.14; H, 4.21; N, 11.54. 
5-Chloro-1-(4-{4-[4-(3-ferrocenyl-acryloyl)-phenoxymethyl]-[1,2,3]triazol-1-yl}-butyl)-1H-pyrimidine-
2,4-dione (5i): Yield 75%. Dark red, solid: m.p 161-162
o
C;  
1
H NMR (DMSO-d6, 500 MHz): 1.54 (t,  
J=6.2Hz, 2H, H
10
), 1.84 (t, J=7.2Hz, 2H, H
9
), 3.72 (t, J=6.3Hz, 2H, H
11
), 4.20 (s, 5H, H
1
), 4.42 (t, 
J=6.4Hz, 2H, H
8
), 4.58 (s, 2H, H
2
), 4.81 (s, 2H, H
3
), 5.22 (s, 2H, H
6
),7.15 (d, J=8.3Hz, 2H, Ar-H) ,7.42 
(d, J=15.4Hz, 1H, H
5
), 7.65 (d, J=15.4Hz, 1H, H
4
), 8.04 (d, J=8.3Hz, 2H, Ar-H), 8.24 (s, 1H, H
7
), 8.25 
(s, 1H, H
12
) ,11.77 (NH-exchangeable with D2O); 
13
C NMR (DMSO-d6, 125 MHz): 25.8,  27.3, 47.5, 
49.3, 61.7, 69.3, 69.7, 71.4, 79.5, 105.6, 115.3, 119.5, 125.3, 131.2, 131.3, 142.4, 145.5, 150.7, 160.3, 
162.5, 187.2. C30H28ClFeN5O4 [M]
+
613.1179.Found: 613.1166. Anal Calcd (%) for: C, 58.70;  H, 4.60;  
N, 11.41.Found:  C, 58.62;  H, 4.49; N.11.34 
5-Chloro-1-(5-{4-[4-(3-ferrocenyl-acryloyl)-phenoxymethyl]-[1,2,3]triazol-1-yl}-pentyl)-1H-
pyrimidine-2,4-dione (5j): Yield 81%. Dark red solid, m.p: 152-153 
o
C; 
1
H NMR (DMSO-d6, 500 
MHz): 1.23-1.28 (m, 2H, H
10
), 1.64 (t, J=6.5Hz, 2H, H
11
), 1.87 (t, J=7.1Hz, 2H, H
9
), 3.69 (t, J=7.0Hz, 
2H, H
12
), 4.20 (s, 5H, H
1
), 4.39 (t, J=7.2Hz, 2H, H
8
), 4.58 (s, 2H, H
2
), 4.89 (s, 2H, H
3
), 5.23 (s, 2H, H
6
), 
7.16 (d, J=8.4Hz, 2H, Ar-H), 7.48 (d, J=15.0Hz, 1H, H
5
), 7.65 (d, J=15.0Hz, 1H, H
4
), 8.10 (d, J=8.4Hz, 
2H, Ar-H) ,8.25 (s, 1H, H
7
), 8.29 (s, 1H, H
13
), 11.78  (NH-exchangeable with D2O); 
13
C NMR (DMSO-
d6, 125 MHz): 23.1,  28.3,  29.5,  48.2, 49.3,  61.5,  69.4,  69.5, 71.3, 79.4, 105.2, 115.3, 119.4, 125.2, 
131.1, 131.3, 142.5, 145.6, 150.6, 160.4, 162.3, 187.3.C31H30ClFeN5O4 [M]
+ 
627.1336. Found: 
627.1324. Anal Calcd (%) for: C, 59.30; H, 4.82; N, 11.15.Found: C, 59.21; H, 4.71; N, 11.21. 
5-Chloro-1-(6-{4-[4-(3-ferrocenyl-acryloyl)-phenoxymethyl]-[1,2,3]triazol-1-yl}-hexyl)-1H-pyrimidine-
2,4-dione (5k): Yield 82%. Dark red solid, m.p: 140-141
o
C; 
1
H NMR (DMSO-d6, 500 MHz): 1.23-1.24 
(m, 4H, H
10
+H
11
), 1.51-1.53 (m, 2H, H
12
), 1.80-1.82 (m, 2H, H
9
), 3.44 (t, J=7.3Hz, 2H, H
13
), 4.02 (s, 
5H, H
1
), 4.25 (t, J=1.3Hz, 2H, H
2
), 4.35 (t, J=7.3, 2H, H
5
), 4.73 (t, J=1.5Hz, 2H, H
3
), 5.22 (s, 2H, H
6
), 
7.13 (d, J=7.1Hz, 2H, Ar
_
H), 7.41 (d, J=15.2Hz, 1H, H
5
), 7.62 (d, J=15.2Hz, 1H, H
4
), 8.05 (d, J=7.1Hz, 
2H, Ar-H), 8.25 (s, 1H, H
7
), 8.29 (s, 1H, H
14
), 11.20 (NH-exchangeable with D2O); 
13
C NMR (DMSO-
d6, 125 MHz): 25.1, 25.3, 28.4, 29.3, 48.4, 49.5, 61.4, 69.3, 69.4, 71.5, 79.5, 106.2, 115.4, 119.5, 125.4, 
131.4, 131.6, 142.2, 145.5, 146.3, 150.1, 160.4, 162.3, 187.2. HRMS calcd for C32H32ClFeN5O4 [M]
+ 
641.1492. Found: 641.1478. Anal Calcd (%) for: C, 59.87; H, 5.02; N, 10.91.Found C,59.73; H, 5.14; 
N, 10.82. 
5-Chloro-1-(8-{4-[4-(3-ferrocenyl-acryloyl)-phenoxymethyl]-[1,2,3]triazol-1-yl}-octyl)-1H-pyrimidine-
2,4-dione (5l) : Yield 82%. Dark red solid, m.p: 130-131
o
C; 
1
H NMR (DMSO-d6, 500 MHz): 1.17-1.19 
(m, 8H, H
10
+H
11
+H
12
+H
13
), 1.55 (t, J=6.3Hz, 2H, H
14
), 1.82 (t, J=6.5Hz, 2H, H
9
), 3.62 (t, J=7.3Hz, 2H, 
H
15
), 4.19 (s, 5H, H
1
), 4.34 (t, J=6.5Hz, 2H, H
9
), 4.55 (s, 2H, H
2
), 4.82 (s, 2H, H
3
), 5.28 (s, 2H, H
6
), 
7.19 (d, J=8.1Hz, 2H, Ar-H), 7.47 (d, J=15.2, 1H, H
4
), 7.56 (s, 1H, H
16
), 7.60 (d, J=15.2, 1H, H
5
), 8.04 
(d, J=8.1, 2H, Ar-H), 8.27 (s,1H,H
7
), 11.15 (NH-exchangeable with D2O); 
13
C NMR (DMSO-d6, 125 
MHz): 26.2,  26.3,  28.3,  28.5, 28.8, 30.2, 47.5,  49.6,  61.7,  69.3,  69.7,  71.3,  79.4, 106.4, 115.3, 
119.1, 125.4, 131.2, 131.5, 142.4, 145.2, 146.3, 151.6, 162.3, 164.3, 187.4. HRMS calcd for 
C34H36ClFeN5O4 [M]
+ 
669.1805. Found: 669.1834. Anal Calcd (%) for: C, 61.95; H, 5.42; N, 
10.15.Found:  C, 61.87;  H, 5.32;  N, 10.07. 
5-Bromo-1-(2-{4-[4-(3-ferrocenyl-acryloyl)-phenoxymethyl]-[1,2,3]triazol-1-yl}-ethyl)-1H-pyrimidine-
2,4-dione (5m) :  Yield 80%, Dark red solid, m.p: 160-162
o
C; 
1
H NMR (DMSO-d6, 500 MHZ): 4.18 (s, 
5H, H
1
), 4.24 (s, 2H, H
9
), 4.50 (s, 2H, H
2
), 4.69 (s, 2H, H
3
), 4.75 (s, 2H, H
8
), 5.26 (s, 2H, H
6
), 7.10-7.12 
(m, 2H, Ar-H), 7.25 (d, J=15.0Hz, 1H, H
5
), 7.64 (d, J =15.0Hz, 1H, H
4
), 7.72 (s, 1H, H
7 
), 8.00-8.03 (m, 
2H, Ar-H), 8.15 (s,1H, H
10
), 11.82 (NH-exchangeable with D2O); 
13
C NMR (DMSO
_
d6, 125 MHz): 
48.0, 48.2, 61.7, 61.8, 69.8, 71.4, 79.3, 95.8, 114.7, 118.9, 125.0, 130.6, 131.5, 143.1, 144.5, 145.6, 
150.5, 159.9, 161.8, 187.2; HRMS calcd for C28H24BrFeN5O4 [M]
+
 629.0361, found  629.0375; Anal 
Calcd (%) for: C, 53.36; H, 3.84; N, 11.11; Found: C, 53.41; H, 3.78; N, 11.22 
5-Bromo-1-(3-{4-[4-(3-ferrocenyl-acryloyl)-phenoxymethyl]-[1,2,3]triazol-1-yl}-propyl)-1H-
pyrimidine-2,4-dione (5n) : Yield  82%. Dark red solid,  m.p: 150-151
o
C; 
1
H NMR (DMSO-d6, 500 
MHz): 2.15-2.17 (m, 2H, H
11
), 3.71 (t,  J=6.3Hz, 2H, H
10
), 4.23 (s, 5H, H
1
), 4.41 (t,  J=6.3Hz, 2H, H
8
), 
4.51 (s, 2H, H
2
), 4.81 (s, 2H, H
3
) , 5.22 (s, 2H, H
6
), 7.18 (d, J=7.6Hz, 2H, Ar-H), 7.44 (d, J=15.2Hz, 
1H, H
5
), 7.64-7.68 (m, 2H, H
5
+H
11
), 8.08 (d, J=7.4Hz, 2H, Ar-H), 8.29 (s, 1H, H
7
), 11.27 (NH-
exchangeable with D2O; 
13
C NMR (DMSO-d6, 125MHz): 29.1, 45.2, 47.2, 61.5, 69.4, 69.7, 71.6, 79.2, 
95.3, 115.2, 119.5, 125.3, 131.5, 131.7, 142.2, 145.8, 145.9, 151.3, 162.2, 164.5, 187.1; 
C29H26BrFeN5O4 [M]
+
 643.0518 Found: 643.0524 Anal Calcd(%) for: C, 54.06; H, 4.07; N, 10.87. 
Found: C, 54.19; H, 3.96; N, 10.74. 
5-Bromo-1-(4-{4-[4-(3-ferrocenyl-acryloyl)-phenoxymethyl]-[1,2,3]triazol-1-yl}-butyl)-1H-pyrimidine-
2,4-dione (5o): Yield  77%. Dark red solid, m.p: 138-139
o
C; 
1
H NMR (DMSO-d6, 500 MHz): 1.59 (t, 
J=6.4Hz, 2H, H
10
), 1.82  (t, J=7.0Hz, 2H, H
9
), 3.70  (t, J=6.7Hz, 2H, H
11
), 4.19 (s, 5H, H
1
), 4.40 (t, 
J=6.7Hz, 2H, H
8
), 4.53 (s, 2H, H
2
), 4.85 (s, 2H, H
3
), 5.26 (s, 2H, H
6
), 7.18 (d, J=8.6Hz, 2H, Ar-H) ,7.45 
(d, J=15.2Hz, 1H, H
5
), 7.63 (d, J=15.2Hz, 1H, H
4
), 8.08 (d, J=8.6, 2H, Ar-H), 8.22  (s, 1H, H
7
), 8.27 (s, 
1H, H
12
), 11.73 (NH-exchangeable with D2O); 
13
C NMR (DMSO-d6, 125 MHz):  25.9,  27.1, 47.7, 49.4, 
61.8, 69.6, 69.9, 71.5, 79.7, 95.1, 115.1, 119.3, 125.1, 131.0, 131.4, 142.6 , 145.7, 150.8, 160.1, 162.1, 
187.0 .C30H27BrFeN5O4 [M]+ 656.0575. Found: 656.0571. Anal Calcd (%) for: C, 55.82; H, 4.14; N, 
10.65. Found: C, 55.75; H, 4.27; N, 10.59. 
5-Bromo-1-(5-{4-[4-(3-ferrocenyl-acryloyl)-phenoxymethyl]-[1,2,3]triazol-1-yl}-pentyl)-1H-
pyrimidine-2,4-dione (5p): Yield 80%. Dark red solid,  m.p:  129-130
o
C; 
1
H NMR (DMSO-d6, 500 
MHz): 1.21-1.26 (m, 2H, H
10
), 1.62 (t, J=6.9Hz, 2H, H
11
), 1.85 (t, J=7.3Hz, 2H, H
9
), 3.65 (t, J=7.0Hz, 
2H, H
12
), 4.19 (s, 5H, H
1
), 4.38 (t, J=7.0Hz, 2H, H
8
), 4.54 (s, 2H, H
2
), 4.85 (s, 2H, H
3
), 5.27 (s, 2H, H
6
), 
7.18 (d, J=8.7Hz, 2H, Ar-H), 7.45 (d, J=15.2Hz, 1H, H
5
), 7.63 (d, J=15.2Hz,1H, H
4
), 8.08 (d, J=8.7Hz, 
2H, Ar-H), 8.21 (s, 1H, H
7
) ,8.26 (s, 1H, H
13
), 11.73 (NH-exchangeable with D2O); 
13
C NMR (DMSO-
d6, 125 MHz): 23.0, 28.2, 29.7, 48.0, 49.6, 61.8, 69.6, 69.9, 71.5, 79.7, 95.4, 115.1, 119.3, 125.0, 131.0, 
131.4, 142.6, 145.7, 150.8, 160.2, 162.1, 187.0. C31H30BrFeN5O4 [M]
+
671.0831.Found: 671.0820. Anal 
Calcd (%) for: C, 55.38; H, 4.50; N, 10.42.Found: C, 55.41; H, 4.38; N, 10.37. 
5-Bromo-1-(6-{4-[4-(3-ferrocenyl-acryloyl)-phenoxymethyl]-[1,2,3]triazol-1-yl}-hexyl)-1H-pyrimidine-
2,4-dione (5q): Yield 85%. Dark red solid: m.p 114-115
o
C; 
1
H NMR (DMSO-d6, 500 MHz): 1.25-1.26 
(m, 4H, H
10
+H
11
), 1.54-1.56 (m, 2H, H
12
), 1.83-1.84 (m, 2H, H
9
), 3.41 (t, J=7.3Hz, 2H, H
13
), 4.04  (s, 
5H, H
1
), 4.23 (t, J=1.5Hz, 2H, H
2
), 4.32 (t, J=7.4Hz, 2H, H
5
), 4.71 (t, J=1.5Hz, 2H, H
3
), 5.25 (s, 2H, 
H
6
), 7.16 (d, J=7.3Hz, 2H, Ar
_
H), 7.45 (d, J=15.3Hz, 1H, H
5
), 7.66 (d, J=15.3Hz, 1H, H
4
), 8.03 (d, 
J=7.1Hz, 2H, Ar-H), 8.23 (s, 1H, H
7
), 8.27 (s,1H, H
14
), 11.24 (NH-exchangeable with D2O); 
13
C NMR 
(DMSO-d6, 125 MHz): 25.3, 25.5, 28.3, 29.5, 48.2, 49.2, 61.3, 69.5, 69.6, 71.3, 79.2, 95.4, 115.2, 119.3, 
125.5, 131.2, 131.4, 142.5, 145.7, 146.5, 150.3, 160.2, 162.1, 187.4. C32H32BrFeN5O4 [M]
+ 
685.0987.Found: 685.0973. Anal Calcd (%) for: C,56.00; H, 4.70; N, 10.20.Found C,56.09; H, 4.62; N, 
10.31 
5-Bromo-1-(8-{4-[4-(3-ferrocenyl-acryloyl)-phenoxymethyl]-[1,2,3]triazol-1-yl}-octyl)-1H-pyrimidine-
2,4-dione (5r): Yield 81%. Dark red solid, m.p: 105-106
o
C; 
1
H NMR (DMSO-d6, 500 MHz); 1.12- 1.15 
(m, 8H, H
10
+H
11
+H
12
+H
13
), 1.54 (t, J=6.4Hz, 2H, H
14
), 1.84 (t, J=6.3Hz, 2H, H
9
), 3.65 (t, J=7.5Hz,  2H,  
H
15
), 4.20 (s, 5H, H
1
), 4.37 (t, J=6.3Hz, 2H, H
9
), 4.58 (s, 2H, H
2
), 4.85 (s, 2H, H
3
), 5.27 (s, 2H, H
6
), 
7.20 (d, J=8.5Hz, 2H, Ar-H) ,7.45 (d, J=15.1Hz, 1H, H
4
), 7.57 (s, 1H, H
16
), 7.62 (d, J=15.1Hz, 1H, H
5
) 
,8.08 (d, J=8.5Hz, 2H, Ar-H), 8.23 (s, 1H, H
7
), 11.13 (NH-exchangeable with D2O); 
13
C NMR (DMSO-
d6, 125MHz): 26.1,  26.2,  28.5,  28.6,  28.8,  30.1, 47.6, 49.7, 61.6, 69.5, 69.6, 71.2, 79.6, 95.4,  115.2, 
119.2, 125.3, 131.3, 131.7, 142.5, 145.5, 146.2,151.4, 162.2, 164.2, 187.0 . HRMS calcd for 
C34H36BrFeN5O4 [M]
+
713.1300.Found: 713.1334. Anal Calcd(%) for: C, 57.16; H, 5.08; N, 9.80. 
Found:  C, 57.29;  H, 4.91;  N, 9.55. 
 
Biological evaluation 
Cell Culture 
Human leukemia cell line (CCRF-CEM, ATCC No. CCL-119) and human breast adenocarcinoma 
(MDA-MB-468, ATCC, No. HTB-132) were purchased from American Type Culture Collection. The 
cells were grown in 75 cm
2 
cell culture flasks with RPMI-16 medium for CCRF-CEM and DMEM for 
MDA-MB-468, supplemented with 10% fetal bovine serum (FBS), 1% penicillin-streptomycin solution 
(10,000 units of penicillin and 10 mg of streptomycin in 0.9% NaCl) in a humidified atmosphere of 5% 
CO2, 95% air at 37 °C. 
 
Cytotoxicity Assay  
 
MDA-MB-468 (5,000 cells), and CCRF-CEM cells (50,0000 cells) were seeded in 0.1 mL per well in 
96-well plates 24 h prior to the experiment. Cells were treated with Dox (5 µM) and DMSO (16.6%) as 
positive controls and compounds 5a-r (50 µM). Plates were incubated for 24 or 72 h at 37 °C in a 
humidified atmosphere of 5% CO2. Before adding MTS reagent [Cell Proliferation Assay Kit 
(Colorimetric) (abcam197010)], the medium of MB-MB-468 was replaced with fresh medium. Cell 
viability was then determined by measuring the fluorescence intensity of the formazan product at 490 
nm using a SpectraMax M2 microplate spectrophotometer. The percentage of cell survival was 
calculated as [(OD value of cells treated with compounds) (OD value of culture medium)] / [(OD value 
of control cells) (OD value of culture medium)] × 100. 
 
 In vitro analysis of cytotoxicity on normal kidney cells 
 
The in vitro cytotoxicity of the compounds was evaluated using normal kidney cell line (LLC-PK1, 
ATCCCL-101), by using the MTS Cell Proliferation Assay Kit. LLCPK cells were seeded at 5,000 cells 
in 0.1 mL per well in 96-well plates. The cells were seeded in medium (EMEM containing FBS (10%)), 
24 h prior to the experiment. The compounds at the concentration of 50 µM were added to each well in 
triplicate and incubated for 24 h or 72 h at 37 °C in a humidified atmosphere of 5% CO2. Doxorubicin 
was used a concentration of 5 µM. Cell viability was then determined by measuring the fluorescence 
intensity at 490 nm using a SpectraMax M2 microplate spectrophotometer. The percentage of cell 
survival was calculated as [(OD value of cells treated with the test mixture of compounds) − (OD value 
of culture medium)]/[(OD value of control cells) − (OD value of culture medium)] × 100%.   
 
 
Results and Discussion 
Chemistry 
Huisgen’s azide-alkyne cycloaddition reaction was employed for the synthesis of desired series of 1H-
1,2,3-triazole-tethered uracil-ferrocenyl-chalcone conjugates. The synthetic methodology involved an 
initial base-promoted propargylation of p-hydroxyacetophenone, followed by its condensation with 
ferrocene-carboxaldehyde in ethanol as reported previously (Kumar et al., 2013). The second precursor 
viz. N-alkylazido 5-substituted uracil derivatives were prepared by hydride-promoted alkylation of 5-
substituted uracil analogues with dibromoalkane followed by its nucleophilic substitution reaction with 
sodium azide. Mono-alkylated uracil is accompanied by the formation of dialkylated uracils albeit in 
poor yields as per literary reports (Dezor-Mazur, Kazmierczak and Golankiewicz, 1984). Cu-promoted 
azide-alkyne cycloaddition reaction between N-alkyl azido-uracils and O-propargylated ferrocenyl-
chalcone afforded the desired 1H-1,2,3-triazole-tethered uracil-ferrocenyl chalcone conjugates that were 
purified via column chromatography using CHCl3:CH3OH (95:5 v/v) mixture as the eluents (Scheme 
1).  
 
 
Scheme 1. Synthesis of compounds 5a-r (a) Dibromo alkanes (1,2 eq), NaH (1.2 eq), DMF, 60 
o
C, 8h (b) NaN3, 
DMF, 60 
o
C, 1h (c) CuSO4.5H2O, Sodium Ascorbate, EtOH:H2O, rt, 12h 
 
The structures of the synthesized uracil-ferrocenyl chalcone conjugates were assigned on the basis of 
spectral data and analytical evidence. The conjugate 5p, for example, showed a molecular ion peak at 
671.0831 (m/z) along with a characteristics signals in 
1
H and 
13
C NMR spectra. Its spectrum 
1
H NMR 
showed the presence of singlet at δ 4.19 corresponding to 5H (cyclopentadiene ring of ferrocene) along  
with two singlets at δ 4.54 (2H) and δ 4.85 (2H) due to the presence of ferrocene ring proton along with 
the  presence of two doublets at δ 7.45 and at δ 7.54 (J =15.2 Hz) corresponding to trans-olefinic 
protons. The presence of characteristic signals at δ 162.1 and 187.0 ppm corresponding to the uracil ring 
carbonyls along with the requisite number of carbons in 
13
C NMR spectrum further corroborated the 
assigned structure 
The synthesized conjugates were evaluated for their cytotoxic profiles against human leukemia cell 
(CCRF-CEM) and human breast adenocarcinoma (MDA-MB-468) cells using MTS-assay, and the 
results are depicted graphically in Figure 1. A standard drug, doxorubicin (Dox) was used as a positive 
control. A number of compounds exhibited substantial cytotoxicity after 72 h incubation. A closer 
inspection revealed the dependence of cytotoxicity on the length of alkyl chain introduced as a spacer 
with a preference for longer chain lengths while the nature of substituents at C-5 position of uracil did 
not seem to influence the activity profiles. The conjugates, having longer alkyl chain lenghts introduced 
as spacer, viz. 5e (n = 6); 5f (n =8); 5j (n = 5); 5k (n = 6); 5p (n = 5); 5q (n = 6), and 5r (n = 8) reduced 
the proliferation of CCRF-CEM cells by approximately 70% after 72 h against. A similar inspection of 
the cytotoxic activities of the synthesized conjugates against MDA-MB-468 revealed that most of the 
conjugates were inactive even after 72 h; the exception being 5a, having an ethyl chain as spacer and 
5d, with a pentyl chain reduced the cell proliferation by 59% and 62%, respectively. 
 
(a) 
 
 
 
 
 
 
 
 
 
(b) 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Cytotoxic activity of compounds 5a-r (50 µM) on (a) CCRF-CEM and (b) MDA-MB-468 cells 
Seven of the most potent conjugates viz. 5e, 5f, 5j, 5k, 5p, 5q, 5r were also evaluated for the cytotoxic 
profiles against normal kidney cell line (LLC-PK1 ATCC CL-101) and the results were compared with 
doxorubicin. As evident, the conjugates with potent activity against CCRF-CEM cell line did not show 
any significant toxicity at a concentration of 50 M after 24 h incubation (Figure 2). Furthermore, the 
compounds were found to be significantly less cytotoxic in non-tumorigenic LLC-PK1 when compared 
with CCRF-CEM cancer cells after 72 h (Figure 1). 
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Figure 2. Cytotoxic activity of 5e, 5f, 5j, 5k, 5p, 5q and 5r (50 µM) against normal kidney cell line 
(LLC-PK1). 
 
Conclusion 
In conclusion, a series of uracil-ferrocenyl chalcone conjugates were prepared via Cu-promoted azide alkyne 
cycloaddition reaction along with an evaluation of their cytotoxic potential against human leukemia and human 
breast adenocarcinoma cell lines. Structure-Activity Relationship (SAR) studies revealed the dependence of 
cytotoxic efficacy on the length of alkyl chain introduced as linker with a number of conjugates exhibiting 
~70% antiproliferative activity against human leukemia (CCRF-CEM) cell line after 72 hours. The synthesized 
conjugates were also found to be significantly less toxic to normal kidney cell line (LLC-PK1, ATCC CL-101). 
Abbreviations 
 SAR, Structure Activity Relationship; CCRF-CEM, ATCC No. CCL-119, Human leukemia cell line; 
MDA-MB-468, ATCC, No. HTB-132, human breast adenocarcinoma; LLC-PK1, ATCCCL-101, 
normal kidney cell line  
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